What is ARS Pharmaceuticals, Inc's share price today?
ARS Pharmaceuticals, Inc (SPRY) share price today is $2.70 as of November 6, 2026 at 10:12 PM IST. The stock touched a day high of $2.80 and a day low of $2.47.What exchange does ARS Pharmaceuticals, Inc stock trade on, and under what ticker symbol?
ARS Pharmaceuticals, Inc stock trades on NASDAQ under the ticker symbol SPRY.What is ARS Pharmaceuticals, Inc's market capitalization?
ARS Pharmaceuticals, Inc's market capitalization is $303.31M as of November 6, 2026 at 10:12 PM IST.What is ARS Pharmaceuticals, Inc's price-to-earnings (P/E) ratio?
ARS Pharmaceuticals, Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.What is ARS Pharmaceuticals, Inc's price-to-book (P/B) ratio?
ARS Pharmaceuticals, Inc's price-to-book (P/B) ratio is 24.20 as of November 6, 2026.Can Indian investors buy ARS Pharmaceuticals, Inc shares?
Yes, You can buy ARS Pharmaceuticals, Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in ARS Pharmaceuticals, Inc shares from India?
Indian investors can buy ARS Pharmaceuticals, Inc shares in three steps: 1. Search ARS Pharmaceuticals, Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from ARS Pharmaceuticals, Inc shares for Indian investors?
Since ARS Pharmaceuticals, Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in ARS Pharmaceuticals, Inc shares via Tickertape?
Indian investors can start investing in ARS Pharmaceuticals, Inc (SPRY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.6968 shares at the current price of $2.70.
$
₹
$2.702.07% (+0.05)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
24.20
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-2.18
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
-184.24%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 4 analysts reports
Buy4 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+818.24%
Earnings Growth
-7.43%
Rev. Growth
+52.57%
Company Profile
Company Profile
ABBV
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$2.65Baseline
Analyst Target - 1 year
Target$24.33+818.24%
All values in $
2026
Current$2.65Baseline
Analyst Target - 1 year
Target$24.33+818.24%
All values in $
Revenue Forecast
Revenue Forecast
Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 52.57% growth, versus a trailing 3-year CAGR of 300.09%.
2025
Current$84.27Baseline
Forecast for Dec 2026
High$139.9+66%
Average$128.58+52.57%
Low$121.3+43.93%
All values in $ Million
2025
Current$84.27Baseline
Forecast for Dec 2026
High$139.9+66%
Average$128.58+52.57%
Low$121.3+43.93%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-1.75Baseline
Forecast for Dec 2026
High$-1.71+2.29%
Average$-1.88-7.43%
Low$-2.06-17.71%
All values in $
2025
Current$-1.75Baseline
Forecast for Dec 2026
High$-1.71+2.29%
Average$-1.88-7.43%
Low$-2.06-17.71%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0.5 | 2.06 | 86.58 | 7.97 | 15.71 | 32.50 | 28.08 | 22.68 | 33.65 |
Gross Profit | -5.23 | -6.39 | 1.95 | 82.68 | 3.92 | 10.73 | 24.31 | 24.88 | 16.39 | 20.81 |
| Net Income | -10.29 | -12.51 | -19.12 | 49.93 | -33.94 | -44.88 | -51.15 | -41.32 | -60.61 | -62.33 |
| Net Profit Margin | - | -2503.2% | -924.95% | 57.67% | -425.68% | -285.56% | -157.38% | -147.12% | -267.26% | -185.21% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc | - | 24.20 | - |
| AbbVie Inc | 50.65 | 50.45 | 0.58 |
| Amgen Inc | 27.73 | 21.33 | 2.75 |
Price Comparison
Price Comparison
Compare SPRY with any stock or ETFCompare SPRY with any stock or ETF
Comparing from
SPRY
ABBV
AMGN
The 12-month consensus target implies 818.24% growth, versus a trailing 3-year CAGR of -9.54%.